SMC accepts vutrisiran for eligible patients in Scotland
The Scottish Medicines Consortium approved vutrisiran for adults with ATTR-CM, enabling access via NHS Scotland. Developed by Alnylam, vutrisiran is a long-acting treatment targeting the underlying biology of the condition. Around 1,800 people in Scotland may be affected. The therapy is also indicated for hereditary ATTR amyloidosis. The decision follows a similar recommendation by NICE in England and Wales.
How this was made
The 30-second read
Why it matters
This is a payer-access milestone for Alnylam’s RNAi therapy in a specific indication and region, following NICE’s recommendation in England and Wales in Dec 2025.
Market read
SMC acceptance can support incremental demand for vutrisiran by expanding reimbursed access, but the article provides no financial magnitude.
What to watch
Actual commercial impact depends on patient identification rates, clinician adoption, and how quickly eligible patients are referred and treated after reimbursement approval.
Background
The Scottish Medicines Consortium (SMC) decision accepts vutrisiran for adults with ATTR-CM, allowing eligible patients to access AMVUTTRA through NHS Scotland.
Ticker impact
Alnylam’s vutrisiran is accepted by Scotland’s SMC for eligible ATTR-CM patients, enabling NHS Scotland access to AMVUTTRA.
Likely modest positive bias as investors price in incremental market access and adoption momentum.
The article is a clear reimbursement milestone tied to Alnylam’s product, but it is geographically limited (Scotland) and lacks financial figures or guidance.
Market effects
Adds another payer acceptance datapoint for RNAi therapeutics in amyloidosis, potentially improving sentiment toward the RNAi platform.
Improves access for ATTR-CM patients in Scotland via NHS Scotland, which can support near-term prescribing and patient flow.
Reinforces the broader European reimbursement trajectory following NICE’s prior recommendation in England and Wales.
Counterpoint
Because the decision is limited to Scotland and provides no revenue or uptake estimates, the market impact may be incremental rather than material.
Key entities
- companyAlnylam UK Limited
Welcomed the SMC decision to accept vutrisiran for eligible ATTR-CM patients in Scotland.
- drugvutrisiran (AMVUTTRA)
Long-acting subcutaneous RNAi therapy dosed every three months, targeting transthyretin protein knockdown.
- regulatorScottish Medicines Consortium (SMC)
Accepted vutrisiran for eligible ATTR-CM patients for NHS Scotland access.
- regulatorNICE
Previously recommended vutrisiran in England and Wales in Dec 2025.
